Effect of L-dopa therapy on plasma homocysteine levels and, consequently, on carotid ıntima-media thickness in Parkinson's disease patients

dc.contributor.buuauthorErer, Sevda Özbek
dc.contributor.buuauthorZarifoğlu, Mehmet
dc.contributor.buuauthorAkgül, Çağdaş
dc.contributor.buuauthorTopal, Naile Bolca
dc.contributor.buuauthorOcakoğlu, Gökhan
dc.contributor.buuauthorKarlı, Necdet
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Radyoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.researcheridAAH-5180-2021tr_TR
dc.contributor.scopusid25635370800tr_TR
dc.contributor.scopusid6603411305tr_TR
dc.contributor.scopusid36981157900tr_TR
dc.contributor.scopusid13806674200tr_TR
dc.contributor.scopusid15832295800tr_TR
dc.contributor.scopusid6506587942tr_TR
dc.date.accessioned2022-09-27T07:11:36Z
dc.date.available2022-09-27T07:11:36Z
dc.date.issued2010
dc.description.abstractObjective: In this study, we investigated hyperhomocysteinemia, as well as carotid intima-media thickness (CIMT) measurements using carotid Doppler ultrasonography, in Parkinson patients on levodopa treatment. Methods: This study was carried out on 23 patients with Parkinson's disease and 21 age-and gender-matched healthy volunteers. Carotid Doppler ultrasonography was performed in order to determine CIMT in all cases. In addition, plasma homocysteine, vitamin B12 and folate levels were measured. Carotid Doppler ultrasonography and homocysteine levels were repeated one year later to evaluate the rate of atherosclerosis progression. Results: Although the population sample was limited, there was an increase in baseline CIMT measurements that occurred in parallel with an increase in baseline homocysteine levels in these patients. At the end of the follow-up period, a bilateral increase in CIMT was observed, which was not correlated to hyperhomocysteinemia. Conclusion: In conclusion, many clinical studies on hyperhomocysteinemia caused by L-dopa therapy in Parkinson patients have been published. However, the relationship between hyperhomocysteinemia and increased risk of vascular disease is still controversial. On the basis of this result, we speculated that hyperhomocysteinemia might lead to an increase in the arterial wall thickness, but its effect on the progression of atherosclerosis is still discussable.en_US
dc.identifier.citationErer, Ö. S. vd. (2010). "Effect of L-dopa therapy on plasma homocysteine levels and, consequently, on carotid ıntima-media thickness in Parkinson's disease patients". Nöropsikiyatri Arşivi, 47(4), 297-301.tr_TR
dc.identifier.endpage301tr_TR
dc.identifier.issn1300-0667
dc.identifier.issue4tr_TR
dc.identifier.scopus2-s2.0-79251586586tr_TR
dc.identifier.startpage297tr_TR
dc.identifier.urihttps://doi.org/10.4274/npa.y5532
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/12682318/
dc.identifier.urihttp://hdl.handle.net/11452/28842
dc.identifier.volume47tr_TR
dc.identifier.wos000285883500006
dc.indexed.scopusScopusen_US
dc.indexed.trdizinTrDizintr_TR
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherTürk Nöropsikiyatri Derneğitr_TR
dc.relation.journalNöropsikiyatri Arşivitr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectParkinson's diseaseen_US
dc.subjectS-adenosylhomocysteineen_US
dc.subjectCarotid artery diseasesen_US
dc.subjectAtherosclerosisen_US
dc.subjectCoronary-heart-diseaseen_US
dc.subjectLevodopaen_US
dc.subjectRisken_US
dc.subjectHyperhomocysteinaemiaen_US
dc.subjectAtherosclerosisen_US
dc.subjectEntacaponeen_US
dc.subjectUltrasounden_US
dc.subjectIncreaseen_US
dc.subjectMarkersen_US
dc.subjectExtenten_US
dc.subjectNeurosciences & neurologyen_US
dc.subjectParkinson hastalığıtr_TR
dc.subjectS-adenozilhomosisteintr_TR
dc.subjectKarotid arter hastalıklarıtr_TR
dc.subjectAteroskleroztr_TR
dc.subject.emtreeCyanocobalaminen_US
dc.subject.emtreeDOPA decarboxylase inhibitoren_US
dc.subject.emtreeFolic aciden_US
dc.subject.emtreeHomocysteineen_US
dc.subject.emtreeLevodopaen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAmino acid blood levelen_US
dc.subject.emtreeArterial wall thicknessen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCarotid arteryen_US
dc.subject.emtreeCarotid atherosclerosisen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDisease courseen_US
dc.subject.emtreeDoppler echographyen_US
dc.subject.emtreeDrug effecten_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHyperhomocysteinemiaen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeParkinson diseaseen_US
dc.subject.emtreeSex differenceen_US
dc.subject.emtreeVitamin blood levelen_US
dc.subject.scopusHyperhomocysteinemia; Cyanocobalamin; Folic Aciden_US
dc.subject.wosClinical neurologyen_US
dc.titleEffect of L-dopa therapy on plasma homocysteine levels and, consequently, on carotid ıntima-media thickness in Parkinson's disease patientsen_US
dc.title.alternativeParkinson hastalarında L-dopa tedavisinin, plazma homosistein düzeyleri ve bununla ilişkili karotis intima-media kalınlıkları üzerine olan etkisitr_TR
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Özbek_vd_2010.pdf
Size:
96.5 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: